No changes were made to the endpoints for the comparison of tirzepatide versus dulaglutide in the expanded population because we observed high concordance with SURPASS-CVOT estimates in the primary composite endpoint as well as mortality in the benchmarking study
Results vary, but common changes include: A subtle glow in 24 sessions Less dull and uneven tone Smoother, healthier-looking skin over time Remember that achieving this result is not an overnight process
conversely, if M2 exosome release is insufficient in the later stages, it predicts impaired repair initiation and a risk of pulmonary fibrosis, at which point the therapeutic focus should shift to pro-reparative strategies (82)
More importantly, it gives them back control
The best dose is not automatically the highest dose
Minimize exposure to moisture and repeated freezethaw cycles